• Zevra’s EU marketing application for arimoclomol in Niemann-Pick disease type C drew a negative opinion from the EMA’s CHMP.
• Re-examination request planned under EU procedures, keeping the product’s European approval timeline uncertain.
• Expanded Access Program to continue supplying arimoclomol to eligible patients while the regulatory path is pursued.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607240730PRIMZONEFULLFEED9767636) on July 24, 2026, and is solely responsible for the information contained therein.